TOPOⅡa与蒽环类新辅助化疗的疗效观察  

Study on relationship between the expression of TOPOⅡa and the effective rate of anthracyline-based neoadjuvant chemotherapy of breast cancer

作　　者：王承正[1] 毛书明[1] 崔树德[1] 

机构地区：[1]河南省肿瘤医院乳腺科,郑州450003

出　　处：《中国肿瘤临床与康复》2009年第1期33-35,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨TOPOⅡa的表达与蒽环类新辅助化疗的疗效关系及新辅助化疗敏感性的预测指标。方法采用免疫组化的方法检测100例乳腺癌患者化疗前TOPOⅡa的表达情况,并评估其与乳腺癌新辅助化疗疗效的关系。结果100例乳腺癌患者,TOPOⅡa的阳性表达率为47.0%;TOPOⅡa的表达状态与化疗疗效及疗效的程度密切相关(P=0.005;P=0.011)。结论TOPOⅡa过表达的患者能从蒽环类化疗中获取更多的益处;TOPOⅡa可能成为预测蒽环类化疗敏感性的独立预后指标。Objective To investigate the relationship between the expression of TOPO Ⅱ a and the effective rate of anthracyline-based neoadjuvant chemotherapy for breast cancer, and investigate the predictive index of sensitivity of breast cancer to neoadjuvant chemotherapy. Methods Expression of TOPO Ⅱ a in breast cancers of 100 patients receiving anthracyline-based neoadjuvant chemotherapy was examined by immunohistochemical method before chemotherapy. The relationship between the expression levels and the effective rate was evaluated. Results Among the 100 cases receiving neoadjvant chemotherapy, the rate of positive TOPO Ⅱa expression was 47.0%. Positive expression of TOPO Ⅱ a was closely correlated with effective rate and response level of anthracyline-based neoadjuvant chemotherapy （ respectively P = 0. 005 ; P = 0. 011 ）. Conclusion Patients with positive expression of TOPO H a may get much benefits from anthracy- line-based chemotherapy. TOPO Ⅱ a can be considered as a predictive marker of the effective rate of anthracyline-based neoadjuvant chemotherapy.

关 键 词：乳腺肿瘤 蒽环类抗生素 拓扑异构酶Ⅱa 新辅助化疗 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]